Team

Making a positive difference to patient experiences and mental health outcomes requires collaboration across disciplines. Our leadership team and actively engaged board, advisors and investors are committed to integrating their diverse expertise in service to patients, their families and society.

Core COMPASS team

Ekaterina Malievskaia MD MSc

Head of Research & Development and Co-Founder

Dr Ekaterina Malievskaia leads Research and Development at COMPASS.

Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia. After her Internal Medicine residency training, she completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York.

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first-hand the challenges in accessing evidence-based and effective mental health care for a family member.

We have created COMPASS to improve patients’ access to innovation in mental health. Through our personal experiences, we have learned how challenging it could be to find the right treatment and right expertise in time. We also learned that it could make all the difference in the outcomes. We walked that path so others don’t have to.

George Goldsmith

Chairman and Co-Founder

George is a serial entrepreneur with significant experience in pharmaceutical regulation.

George's early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science.His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks' Non-Executive Chairman. George also serves on the board of directors for AnaBios, a company redefining drug discovery. He and his wife, Ekaterina Malievskaia MD, live in London.

I have spent my life working with teams of leaders seeking to do extraordinary things. The best of them fight the tendency to accept zero-sum strategies and declare victory. They understand that we can create environments where people suspend disbelief, build trust and chase unlikely combinations of new ideas and technologies.

Lars Christian Wilde

Chief Operating Officer and Co-Founder

Lars is Co-Founder and Chief Operating Officer of COMPASS Pathways, focusing on operations, digital health solutions and fundraising.

Lars is also active as a business angel investor and advisor, and has helped to successfully build companies such as Otto Wilde Grillers and Emma & Noah. Before joining COMPASS, Lars was the founder and CEO of Springlane, the leading German kitchen equipment online retailer and the largest German cooking magazine. Being a hobby chef himself, Lars realised that cooking was moving from being a daily chore to becoming an interest for an increasingly large number of people. Exploiting this, Lars built Springlane from a two person business into a company that produces its own brands and product ranges, is active in several European countries, runs offline retail stores, and has raised more than 30m EUR in capital from some of the leading European venture capital firms. Lars previously worked as an investor at Waterland Private Equity, the world’s best performing private equity fund. Amongst other buy-and-build investments, he focused on building VivaNeo, the largest European in-vitro fertilization group, providing patients with cutting edge medical solutions. Lars has also spent time with Boston Consulting Group in Munich and Sao Paulo. Lars holds a Masters in Finance with distinction from IE Business School in Spain and a Bachelor of Science in Business Administration with distinction from Rotterdam School of Management, Erasmus University in the Netherlands. Lars spent exchange semesters at Westfälische Wilhelms-Universität Münster, Copenhagen Business School and the Ross School of Business at the University of Michigan.

I have witnessed how devastating the impact of depression can be on a person’s life in my close circle of friends. My friend had the privilege of being treated with psilocybin and he has been relieved of the debilitating disease ever since. Unfortunately, this treatment is not available to most people in the world and its efficacy has yet to be proven in large scale clinical trials. Having founded and invested in several companies in the past, I recognised that COMPASS offers the opportunity to build something immensely beneficial for our global society. I am excited by the outlook of solving one of humanity’s largest unmet medical needs together with an extremely smart and vision driven team.

Hans Eriksson

Chief Medical Officer

Hans is Chief Medical Officer of COMPASS Pathways, leading the clinical development programme.

Hans gained his MD and did his residency in psychiatry at Lund University in Sweden. He also holds a PhD in Cell and Molecular Biology from Lund University, and an executive MBA from Stockholm School of Economics. After having worked as consultant psychiatrist and assisting head of the Psychiatric Centre at Lund University Hospital, he moved to the pharmaceutical industry in 2000. He has been working in different roles with H. Lundbeck and AstraZeneca, especially on the development programmes for escitalopram, quetiapine XR, mecamylamine, and brexpiprazole for major depressive disorder, and for additional psychiatric indications. He had an active role in the successful regulatory submissions of Cipralex, Seroquel XR and Rexulti. He was the global medical lead for Seroquel XR at AstraZeneca, and in his most recent role he was Senior Director and head of clinical development for depression and paediatrics at H. Lundbeck. At COMPASS Pathways, Hans uses his clinical expertise and clinical development experience to lead the development programme.

It is a truly meaningful effort to participate in the development of a novel treatment paradigm for people suffering from severe mental disorders.

Marco Mohwinckel

Chief Commercial Officer

Marco is Chief Commercial Officer at COMPASS Pathways, leading on commercial strategy.

Throughout his career, Marco has been an outspoken advocate for change, innovation and entrepreneurship in healthcare. Over the past 15 years he led strategy and commercial operations for digital and pharmaceutical companies across various therapeutic areas and continents. Most recently he was VP of Strategy at WebMD / Medscape, the leading online health information platform for consumers and healthcare professionals; previously he worked at Johnson & Johnson as Global Head of Janssen Healthcare Innovation, where he was part of the Global Commercial Strategy Leadership Team, and as head of the Neuroscience Business Unit in the UK. As management consultant at the Monitor Group, he advised life-science and technology companies on growth strategies, market access, product launches, operational excellence, business development and strategic partnerships. Marco is an active advisor and independent board member in several health-tech start-ups and digital health networks. He engages in public speaking on digital health innovation and has co-authored several articles, most notably “Beyond magic bullets: True Innovation in Healthcare” (Nature Reviews Drug Discovery, 2013), arguing for the need to develop holistic solutions and new business models for patients suffering with mental illnesses.

In the next few years, we will see significant breakthroughs in the treatment of many 'silent' and debilitating mental health conditions, like depression, which affect millions of people around us. Having worked in this field for years, I am excited to be part of COMPASS on a pioneering mission to build and cross bridges that lead to a better future; one without prejudice or stigma, where empowered individuals have universal access to the best possible treatment and support.

Joe Heinen

Chief Financial Officer

Joe is a senior finance professional with over 15 years of experience working with entrepreneurs to establish and lead early-stage companies in the US and Europe.

Joe has been working with COMPASS from the beginning. He is responsible for the financial operations of the firm. Joe is also the CFO of Tapestry Networks, a Boston-based professional services firm focused on helping leaders of some of the world’s most important institutions do their work more effectively and with greater confidence. Prior to Tapestry and COMPASS, Joe worked as an independent consultant offering CFO services to early stage companies and, before that, he worked in fixed income sales and trading with Goldman Sachs in New York. Joe earned a undergraduate degree in engineering from the University of Wisconsin and a master’s degree in finance from the Kellogg School of Management.

I‘ve known George & Katya for years and their passion for building an organisation that could one day provide access to this innovative therapy for millions of patients suffering from debilitating mental illness was contagious. I knew early on that I wanted to be on this journey with them.

John Boghossian

Director of Operations

John is Director of Operations at COMPASS. He focuses on daily operations, Market Access and commercial strategy, partnerships, and fundraising.

Before joining COMPASS, John attended the Harvard Business School (HBS) for an MBA. During and after his studies he co-founded a technology company focused on enterprise productivity software. Before HBS, he worked at the Boston Consulting Group (BCG) and specialised in healthcare. He advised global pharmaceutical companies as well as hospital networks across Western Europe and North America. His experience includes R&D strategy, new drug market access strategy, and value-based healthcare outcome measurement. Before BCG, John graduated from the Massachusetts Institute of Technology (MIT) with bachelors in mechanical engineering and economics with distinction, and from the University of Cambridge with a masters in Energy Technologies with distinction. An avid traveller, he calls both sides of the Atlantic home.

My goal is to work on a mission-driven early-stage venture with like-minded people. The mission of COMPASS aligns perfectly with my belief in innovative outcome-based healthcare delivery models, in a therapeutic area with significant unmet medical need. I'm excited to be, together with the whole COMPASS team, on the journey to provide new alternatives to mental health disorders like treatment-resistant depression worldwide.

Tracy Cheung

Director of Communications

Tracy Cheung has more than 25 years’ experience in strategic communications, working with senior executive teams on public affairs, investor and media relations, corporate communications, marketing communications and employee engagement.

Tracy began her career in communications consultancy, working at Rowland Sallingbury Casey and Brunswick. She has since led communications teams in a number of healthcare and life sciences organisations, including Amersham International, GE Healthcare Medical Diagnostics and Essentia (part of Guy’s and St Thomas’ NHS Foundation Trust). Tracy is also a coach with Parent Gym, an evidence-based philanthropic programme designed to support parents in raising happy and confident children.  

What I love about COMPASS is the absolute commitment to putting patients at the centre of everything we do, and the determination to help those suffering with mental illness.

Sue Stansfield

Director of Clinical Trial Programme

Sue is Director of Clinical Trials at COMPASS, leading the global clinical trials programme.

Sue gained her PhD in neuroendocrinology in the 1980s and began her career at Wellcome Research Labs, working on the successful registration of Lamictal®. She moved onto Janssen and Parke-Davies in increasingly senior roles in CNS drug development (anxiety, depression, epilepsy, Alzheimer’s Disease). In 1991, Sue joined Quintiles as the Global Project Director leading the development of a reversible inhibitor of monoamine oxidase A (RIMA) towards an NDA (US new drug application) in panic disorder and social phobia with line extension outside USA. From there, Sue pursued a career in the Clinical Research Organisation (CRO) industry that spanned 25 years. She has worked for a number of leading CROs including Quintiles (now IQVIA) PPD, PRA, Premier Research and inVentiv Health (now Syneos Health), successively expanding her remit with additional functions and regions. At COMPASS Pathways, Sue combines her scientific experience with her trial execution expertise to develop and lead the clinical trials programme.

It is so refreshing to work in such a dynamic team with one single agenda; to overcome the barriers in order to benefit patients.

Sarah Drummond

Executive Personal Assistant

Sarah is an Executive Personal Assistant with over 20 years’ experience.

Before joining COMPASS she worked as George Goldsmith’s Executive PA at Tapestry Networks, a company dedicated to bringing together leaders from business and institutions to help make the world better by making it run better,  for 10 years.  During her time as an EA she has worked in a number of different sectors in London including surveyors, media, finance, consulting and professional services.

I believe COMPASS can make a real and positive difference to the unmet medical needs surrounding mental health and well-being.

Molly Lennard-Jones

Therapist Training Coordinator

Molly focuses on therapist training, therapist recruitment, and is working on qualitative research projects.

Before joining COMPASS, Molly studied English Literature at masters level looking at PTSD in Holocaust Literature. This sparked an interest in mental health research and lead to her to pursue a career in clinical trials; so that she could help translate academic research into real-life treatments. It is this that lead her to COMPASS.

“Working at COMPASS, every day brings new challenges; and with that comes the opportunity to learn from a highly motivated and talented team whose primary philosophies are grounded in patient empowerment. Being a part of something that will make positive impacts on the lives of patients is truly incredible.”

Manon Veraart

Director of Business Development

Professional with over 5 years of experience in investment banking and management consulting and a background in psychology. At COMPASS, Manon focuses on operations, investor relations and partnerships.

Prior to joining COMPASS, Manon worked at the Boston Consulting Group (BCG) in London. She joined BCG after graduating from the INSEAD MBA programme (with distinction). During her MBA, she completed an internship at Aleph Capital Partners (investment firm). Before INSEAD, Manon worked first as an Analyst and later as an Associate in the Natural Resources M&A team of Goldman Sachs in London. Manon is originally from the Netherlands and holds a Master (with distinction) and Bachelor in Business Administration from Erasmus University (Rotterdam) and a Bachelor in Psychology from Leiden University. Manon spent exchange semesters at the University of Southern California, Los Angeles and INCAE, Costa Rica.

I love being part of a highly diverse and collaborative team that is working hard to relieve and solve mental health problems; an issue so many people struggle with. Being able to work on this together, with the ultimate goal of empowering patients globally, motivates me every day.

Samuel I Williams

Associate Project Manager, Clinical Trials Programme

Sam is the Associate Project Manager of the Clinical Trials Programme at COMPASS. He focuses on planning, managing and executing the procedures required for clinical trial progression. 

Sam started working in clinical research during his Master’s degree and has been in this line of work ever since. After graduating, Sam worked at PAREXEL and Covance in different project management support roles in clinical technology solutions and clinical operations. Following this, Sam worked in the NHS, in research service delivery. His most recent post before joining COMPASS, was as the Research Manager for the Acute Medicine Directorate at Guy’s and St Thomas’ NHS Foundation trust. Here, Sam oversaw and advised different teams, the set up and management of commercial and non-commercial trials and research governance across the different clinical services in the directorate.

The innovative approach to therapy, the team of experts and the real drive to empower patients makes being part of the COMPASS team truly an amazing experience.

Monique Superville

Associate Project Manager, Clinical Trials Programme (North America)

Monique is responsible for managing clinical trials operations across the US and Canadian sites.

Prior to joining COMPASS, Monique was the QA/I Manager at NYU School of Medicine where she managed a team of clinical research auditors. Before NYU, she performed clinical research audits as a Senior Human Subjects Protection Analyst at Rutgers University. Prior to Rutgers, she was the Compliance Oversight Manager at Columbia University IRB where she led a clinical research audit team. At all three institutions, the audit activities crossed all medical disciplines. In addition to audits, she assisted researchers with external inspection preparation, study team development and education, and the writing and implementation of Correction and Preventative Action (CAPA) plans. Monique holds a Master of Arts in Applied Psychology from Columbia University and a Bachelor of Arts from The New School for Social Research. She is also a Certified Clinical Research Professional (CCRP).

It’s exciting to be part of a team of talented people with such a broad variety of experience, coming together to accomplish something truly groundbreaking.

Rachel Winzer

Therapist Training Programme Coordinator (North America)

Rachel is responsible for the roll-out and implementation of COMPASS' therapist training across US and Canadian sites. 

Before joining COMPASS, Rachel worked as a mental health specialist at the McLean Franciscan inpatient psychiatric unit in Boston, helping patients and their families manage a wide variety of challenges. Before McLean, Rachel was a behavioral treatment counselor at Germaine Lawrence in Boston, a residential treatment center for adolescents, specializing in trauma and PTSD. Rachel holds a Master of Science in Social Cognition (with distinction) from University College London and a Bachelor of Psychology from University of Colorado Boulder.

“Being a part of the COMPASS team and collaborating with like-minded individuals to further human-centered research and improve lives ignites a sense of purpose and passion in me. We are motivated daily by our collective desire to break down barriers to high quality treatment and combat mental health issues with innovative therapies.”

Anais Soula

Research Analyst

Anais focuses on the design of the Phase 3 clinical trial and market access strategy.

After graduating, with distinction, from a Master’s in Cellular Biology, Physiology and Pathology at the University of Bordeaux, Anais obtained fellowships from the French Ministry of Education and the Fondation pour la Recherche Medicale to carry out her PhD in Molecular Biology and Neuroscience at the Interdisciplinary Institute for Neuroscience. During her PhD, Anais explored new ways of communication between brain cells based on the exchange of extracellular vesicles. Keen on integrating cutting-edge science into society, she pursued a Master’s in Technology and Innovation Management alongside her PhD at the University of Paris-Sud.

At COMPASS, I hope to leverage my scientific background to contribute to the creation of novel treatments for mental health problems.

Jessica Rose Stuart

Team Coordinator

Jess focuses on enabling the COMPASS team to implement the clinical trials programme effectively by providing efficient administrative support.

Jess graduated from Warwick University with a degree in English and American Literature and developed a passion for psychology through voluntary work undertaken during her studies. Jess worked in the media for a number of years before joining a psychology practice, The House Partnership. As Practice Manager, she gained extensive administrative experience in the mental healthcare field by fulfilling a wide range of responsibilities, which included acting as the first point of contact for clients seeking talking therapy and providing diary management for a team of 15 psychologists.

It is incredibly motivating to be part of an accomplished and dedicated team who share the belief that it is possible to end the suffering caused by mental health disorders. Supporting COMPASS to implement an innovative and patient-centred approach to treatment is refreshing and truly inspiring

Nisha Thiara

Operations Coordinator

Part of the operations team, Nisha is responsible for daily management of North American and European clinical research sites as part of our trials.

Nisha is an Operations Coordinator at COMPASS. She ensures all clinical research sites are fully equipped for upcoming trials and is the first point of contact for trial coordinators at the sites. Nisha graduated from King's College University with a distinction, studying a Master's degree in Early Intervention in Psychosis. While at King's, Nisha became increasingly aware of the gaps in treating mental disorders and the real need for innovative patient-centred interventions.

It feels inspiring to be apart of a new wave in treating psychiatric-related disorders. Working in a passionate, driven workplace with bright minds, all working towards accelerating patient access makes working for COMPASS a truly rewarding experience.

Board of Directors

Ekaterina Malievskaia MD MSc

Head of Research & Development and Co-Founder

Dr Ekaterina Malievskaia leads Research and Development at COMPASS.

Ekaterina received her medical degree from St Petersburg Medical Academy in St Petersburg, Russia. After her Internal Medicine residency training, she completed an Environmental Medicine Fellowship at Mount Sinai School of Medicine and received her MSc in Public Health from New York University Medical School. She worked in private practice, academic medicine and public health for more than 15 years in the greater New York area. She was a Clinical Instructor of Medicine at Mount Sinai School of Medicine, as well as a Research Professor at City University of New York.

After moving to London in 2011, Ekaterina worked in global health and medical philanthropy, focusing on improving outcomes in maternal and child health. She founded COMPASS Pathways with her husband George Goldsmith in 2016, having experienced at first-hand the challenges in accessing evidence-based and effective mental health care for a family member.

We have created COMPASS to improve patients’ access to innovation in mental health. Through our personal experiences, we have learned how challenging it could be to find the right treatment and right expertise in time. We also learned that it could make all the difference in the outcomes. We walked that path so others don’t have to.

George Goldsmith

Chairman and Co-Founder

George is a serial entrepreneur with significant experience in pharmaceutical regulation.

George's early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science.His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks' Non-Executive Chairman. George also serves on the board of directors for AnaBios, a company redefining drug discovery. He and his wife, Ekaterina Malievskaia MD, live in London.

I have spent my life working with teams of leaders seeking to do extraordinary things. The best of them fight the tendency to accept zero-sum strategies and declare victory. They understand that we can create environments where people suspend disbelief, build trust and chase unlikely combinations of new ideas and technologies.

Christian Angermayer

Member of Board of Directors and Founding Seed Investor

Christian is the Founder and Chief Executive Officer of Apeiron Investment Group Ltd. The Group's sector focus is on financial services, technology, life sciences, media, real estate and natural resources; its regional focus is on Germany and Africa.

Christian co-founded ADC African Development Corporation AG and serves as its Senior Advisor. He is also Founder and Chairman of Film House Germany AG and a former Consultant at Altira ADC Management GmbH. He is a Supervisory Board Member of the Cinema for Peace Foundation and co-host of the annual Cinema for Peace Award. Since 2011, he has been a Member of the Young Global Leaders programme of the World Economic Forum. He is a member of the Presidential Advisory Council of President Paul Kagame of Rwanda, and an active member of the Clinton Global Initiative. Merging his profound experience at the nexus of traditional financial services and technology, he is one of the most active and significant investors in European fintech companies with a special focus on cryptocurrencies and blockchain-related business models. Christian has created several successful companies, many now public, including the African Banking Holding ADC, Ribopharma, which is listed on the stock market as Alnylam Pharmaceuticals. He has served as Chief Executive Officer of VCH Investment Group AG, of VCH Equity Group, and of Angermayer, Brumm & Lange Group; and as Chief Scientific Officer at FinLab AG. He was previously a Vice Chairman of the Supervisory Board at Deag Deutsche Entertainment Ag. He studied Business Administration at the University of Bayreuth, Germany.

Annalisa Jenkins MBBS

Independent Director

Annalisa is a senior biotech executive, the Executive Chairman at Vium and a Non-Executive Director at eight other biotech companies.

Annalisa was previously Head of R&D at Merck Serono and Global Medical Senior Vice-President at Bristol-Myers Squibb. She is the CEO of PlaqueTec - a company driving the future of personalised medicine in coronary artery disease, in addition to chairing or serving on the boards of a number of private and public companies in the life sciences industry, located in the U.S. and U.K.

Thomas Lönngren

Independent Director

Thomas Lönngren is a senior regulatory Executive, and served as Executive Director of the European Medicines Agency (EMA) from 2001-2010.

Thomas is currently Director at Pharma Executive Consulting and Strategic Advisor at the NDA Group. His greatest achievement is heading the European Medicines Agency for 10 years taking it from a relatively unknown agency in 2001 to become recognised together with the US FDA as a world leader in drug regulation. Based on his extensive experience and knowledge of drug/device regulation, approval, market access, management, strategy and leadership, he currently advises pharmaceutical companies worldwide on drug development with a focus on regulatory and market access. He also serves as a non executive board member, participates in scientific Advisory Boards and frequently speaks at conferences around the world.

David Norton

Independent Director

David Norton is a senior Biopharma Executive, and the former Company Group Chairman of Global Pharmaceuticals at Johnson & Johnson.

David is currently a Director at two other life sciences companies. He has also been a standout as Board member and benefactor of Alliance For Aging Research, a national non-profit organisation, which seeks research-based, innovative solutions to the health problems of aging populations.

Paolo Siviero

Member of Board of Directors and Series A Investor

Paolo is Head of Investments for Principia III, the first Italian VC and PE fund entirely dedicated to life sciences investments, and formerly Head of Strategy and Policy on Medical Products Area at AIFA (Italian regulator).  

At Agenzia Italiana del Farmaco (AIFA), Paolo was responsible for establishing prices and refundability of medicines, evaluating HTAs and checking pharmaceutical expenditures. Prior to joining AIFA, he was Chairman of MEDEV Group and a Board Member of the European Medicines Agency (EMA). Paolo has extensive experience investing in life sciences companies, including AnaBios, Enterome, and Ixaltis. For more information about Principia, please visit their website: https://principiasgr.it/

Scientific Advisory Board

Prof David Nutt DM FRCP FRCPSYCH FSB FMEDSCI

Chair of Scientific Advisory Board

Professor David Nutt is the Edmond J Safra Chair in Neuropsychopharmacology at the Imperial College London. He is also the President of the European Brain Council, and the former President of the European College of Neuropsychopharmacology.

Professor Nutt is a British neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He was until 2009 a professor at the University of Bristol heading their Psychopharmacology Unit. Since then he has been the Edmond J Safra chair in Neuropsychopharmacology at Imperial College London and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences there. Nutt was a member of the Committee on Safety of Medicines, and was President of the European College of Neuropsychopharmacology. His book Drugs Without the Hot Air (UIT press) won the Transmission Prize for Communicating Science in 2014.

Prof Sir Alasdair Breckenridge CBE FRSE

Member of Scientific Advisory Board

Alasdair Breckenridge was Chairman of the Medicines and Healthcare products Regulatory Agency which was formed in April 2003 by the merger of the Medicines Control Agency and the Medical Devices Agency.  Previously he was Chairman of the Committee on Safety of Medicines and Professor of Clinical Pharmacology in the University of Liverpool. He is now Chairman of the Advisory Board of the Centre of Regulatory Excellence of Duke/NUS in Singapore. He was knighted in 2004. 

During his tenure at MHRA, Sir Alasdair served as the first Chair of the Department of Health’s Emerging Science and Bioethics Advisory Committee (ESBAC), an organisation responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council and he worked closely on several programmes of the European Union, the World Health Organisation and the International Union of Pharmacology and as Chair of the Committee on Safety of Medicines.  

As a regulator, I am intrigued by the possible use of a drug with a previously uncertain reputation in a novel situation and how the regulatory hurdles could be overcome. To take a drug from the 1950s and reposition it in modern medicine especially for an unmet medical need presents a series of fascinating challenges.

Robin L Carhart-Harris PhD

Member of Scientific Advisory Board

Dr Robin Carhart-Harris is Director of the Centre for Psychedelic Research at Imperial College London.

Dr Carhart-Harris moved to Imperial College London in 2009 after obtaining his PhD in Psychopharmacology from the University of Bristol, and prior to that, an MA in Psychoanalysis at Brunel University. At Imperial, he has worked on a series of brain imaging studies into the brain effects of psilocybin, MDMA, LSD and DMT, plus two clinical trials of psilocybin for depression. In 2015 he founded the Psychedelic Research Group at Imperial, which he runs. He has an honorary position at the University of Oxford.

I admire COMPASS' vision and ability not just to talk but to deliver. For the sake of patient access, I hope and believe they will succeed and am keen to help them actualise this.

Tom Insel MD

Member of Scientific Advisory Board

Thomas Insel MD is a psychiatrist and neuroscientist who served as Director of the US National Institute of Mental Health (NIMH), Professor of Psychiatry at Emory University and founding director of the Centre for Behavioural Neuroscience in Atlanta.

Tom is a psychiatrist and neuroscientist. From 2002-2015, he served as Director of the US National Institute of Mental Health (NIMH), the component of the US National Institutes of Health (NIH) committed to research on mental disorders. Prior to that, he was Professor of Psychiatry at Emory University where he was founding director of the Center for Behavioral Neuroscience in Atlanta. He led the mental health team at Verily (formerly Google Life Sciences) from 2015-2017. He is also a member of the US National Academy of Medicine and has received numerous national and international awards including honorary degrees in the US and Europe. He is currently Co-founder and President of Mindstrong Health.  

Mental healthcare needs innovation. The traditional model of care delivery is often built around the needs of providers and payers not the preferences of patients and families. As a result, most people with mental illness avoid getting care. When they seek help, patients are likely to receive medications, psychosocial therapies, or devices but not an integrated plan that provides all the potential interventions in a personalised, evidence-based approach. The COMPASS medication-assisted psychotherapy strategy is innovative in that it integrates medication and psychotherapy. And it is disruptive by offering patients a treatment that many people prefer. I have chosen to be involved with COMPASS because I believe that this approach has potential but needs to be validated in rigorous, controlled clinical trials. My goal is to help COMPASS set a high bar for science so that, should the data be supportive, patients and families can trust that medication-assisted psychotherapy is an evidence-based approach.

Luca Pani MD PhD

Member of Scientific Advisory Board

Dr Luca Pani is former Director General of the Italian Medicines Agency (AIFA). He is currently Executive Director of Global Medical Innovation at NeuroCog.

Luca is former Director General of the Italian Medicines Agency (AIFA) and a globally recognised expert in psychiatry, pharmacology and molecular biology.  As Executive Director of Global Medical Innovation, Luca guides the company’s development of innovative solutions for clinical trials methodologies and health outcomes. During his tenure as Director General of AIFA, Dr. Pani pioneered several new approaches to drug approval, pricing, and reimbursement strategies by using advanced informatics to follow and certify real-world data. These models have now been adopted in many other countries. As a European regulator, Luca has been a leading figure for approval and scientific advice for CNS products and served as Chair of the Telematics Committee. He has authored or co-authored hundreds of publications and served on the editorial boards of many scientific journals, including Clinical Neuropsychiatry. He is Professor of Psychiatry at the University of Miami. Luca earned his medical degree from the University of Cagliari, psychiatry degree from the University of Naples and completed post-doctoral training in molecular biology and pharmacology at the University of Illinois and Georgetown University.

Diego Pizzagalli PhD

Member of Scientific Advisory Board

Diego Pizzagalli is an experimental psychologist and neuroscientist. He is a Professor of Psychiatry at the Harvard Medical School. At the McLean Hospital, he is the Director of the McLean Imaging Center, the Director of the Center for Depression, Anxiety and Stress Research, the Director of Research at the Division of Depression & Anxiety Disorders, as well as the Director of the Laboratory for Affective and Translational Neuroscience.

From 2002-2010 he was a faculty member in the Department of Psychology at Harvard University. In 2010, he was recruited to McLean Hospital to serve as the Founding Director of the newly established Center for Depression, Anxiety and Stress Research (CDASR), as well as the Director of the McLean Imaging Center (MIC). Since September 2015, he also serves as the Director of Research for the Division of Depression and Anxiety. He is currently a Professor of Psychiatry at Harvard Medical School. The main goals of his research are to improve our understanding of the psychological, environmental, and neurobiological factors associated with mood disorders, particularly major depression. To this end, he integrates behavioral, electrophysiological, neuroimaging, and, more recently pharmacological, approaches to investigate three putative endophenotypes of depression: anhedonia (loss of pleasure), increased stress sensitivity, and executive dysfunction. Dr. Pizzagalli has published over 170 papers and chapters and serves on the editorial board of 10 journals. Among several awards, he received the Distinguished Scientific Award for an Early Career Contribution to Psychophysiology from the Society for Psychophysiological Research (2006), the Early Career Award from the EEG and Clinical Neuroscience Society (2007), a MERIT award from the National Institute of Mental Health (2016), the Joel Elkes Research Award from the American College of Neuropsychopharmacology (2017), and a NARSAD Distinguished Investigator Award (2018).

Currently available antidepressant treatments (e.g., medications, evidence-based psychotherapy) work well for many individuals, but up to 45% of individuals with major depression fail to respond to available interventions. Thus, there is an acute unmet need to develop novel treatment strategies for our patients.

John Rush MD

Member of Scientific Advisory Board

Dr Rush is a professor of psychiatry with positions including Professor Emeritus at Duke-National University of Singapore (Duke-NUS) and CEO of Curbstone Consultant LLC.

John's 45-year academic career has focused on the psychology and biology of mood disorders. His work has led to the development and evaluation of innovative treatments (medications, somatic treatments, psychotherapy), disease management protocols and clinical tools to improve early detection and care for persons with mood disorders and their families. He is the author of more than 800 professional publications and the recipient of numerous awards. He was recognised as one of the “World’s Most Influential Scientific Minds” by Thomson Reuters in 2014.

The focus on improving the treatment of depression, the rigorous scientific approaches being considered and the quality of the scientific team being formed were important elements in my consideration to join COMPASS, as was the strong commitment of the COMPASS leadership. The development and rigorous testing of the potential antidepressant effects of psilocybin, if successful, would be a scientific and therapeutic paradigm-changing contribution, opening new avenues to additional treatment innovations for other neuropsychiatric conditions. The opportunity to make this kind of contribution is a rare privilege.

Prof Alan Schatzberg MD

Member of Scientific Advisory Board

Director at the Stanford Mood Disorders Center and Professor of Psychiatry at the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine.

Alan Schatzberg MD has been the Kenneth T Norris, Jr Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine since 1991. He previously served as the President of the American College of Neuropsychology, the Society of Biological Psychiatry, and the American Psychiatric Association (APA). From 1991- 2010, Alan served as the Chair at Stanford University School of Medicine, Psychiatry, and Behavioural Sciences. He has published over 362 publications, 98 of which are featured publications holding significance in the academic field. He is also the co-editor-in-chief of the Journal of Psychiatric Research. Alan has received multiple national and international awards and honours, including the Judd Marmor Award for Biopsychosocial Research and the Distinguished Service in Psychiatry Award from the American Psychiatric Association (2018), the Lifetime Achievement Award from the International Society of Psychoneuroendocrinology (2015), and the Society of Biological Psychiatry Gold Medal Award (2015). He is a member of THE Bio-X and Wu Tsai Neurosciences Institute. Alan earned his medical degree from Harvard University, before completing his medical training at the New York University of Medicine. He is board certified in psychiatry and holds a fellowship granted by Harvard Medical School.

Prof Paul Summergrad MD

Member of Scientific Advisory Board

Prof Paul Summergrad MD is the Dr Frances S Arkin professor and chairman of the Department of Psychiatry and professor of medicine at Tufts University School of Medicine and psychiatrist-in-chief at Tufts Medical Center. He is the past president of the American Psychiatric Association. 

Paul has served as founding chairman of the Tufts Medical Center Physicians Organization since 2005 and is a former president of the American Psychiatric Association (APA) and of the American Association of Chairs of Departments of Psychiatry. He is a member of the Tufts Medical Center and the Wellforce boards of trustees, and co-chairs the Tufts University Mental Health Task Force.

An international leader in medical psychiatric illness and care, his research focuses on mood disorders, medical-psychiatric illness, and health system design. He has published extensively with more than 100 peer review publications, books, book chapters and other communications. He serves on the editorial boards of Academic Psychiatry, Current Psychiatry and Personalized Medicine in Psychiatry. A sought-after speaker, educator and consultant, he has served as a visiting professor and been invited to give lectures across the world. He is a member of the Diagnostic and Statistical Manual 5 Steering Committee of the American Psychiatric Association and the Standing Committee on Nominations of the World Psychiatric Association. He is a distinguished fellow of the American Psychiatric Association, a fellow of the American College of Psychiatrists and of the American College of Physicians, and has received numerous other awards and honours including Castle and Connolly’s America’s Top Doctors from 2011 to the present, and the Distinguished Faculty Award from Tufts University School of Medicine.

Paul earned his degree from the School of Medicine at the State University of New York, before completing his training in internal medicine at Boston City Hospital and Boston University School of Medicine and in psychiatry at Massachusetts General Hospital and Harvard Medical School, where he was chief resident and a clinical fellow in psychiatry. He is board certified in both psychiatry and internal medicine.

The limitations of currently available treatments for psychiatric illnesses has led to investigating agents which have been previously abandoned or used for other purposes. Recent pilot research has suggested a possible benefit for some psychoactive agents. Given the complex history of these agents, it requires great care and highly responsible leadership to do larger scale clinical studies. The leadership of Compass Pathways brings extraordinary skills and experience. Their track record of entrepreneurship, clinical excellence and rigorous attention to oversight of complex endeavors convinced me that they would be able to pursue this research in a manner which would reflect both the opportunities and challenges in finding new treatments for refractory psychiatry disorders.

Kirk Rutter

Special Advisor, Patient Experience

Kirk is a technologist for a London University. He became a volunteer patient on the 2015 Imperial College clinical study of psilocybin therapy for treatment-resistant depression (TRD). 

Driven by the scheduled status of psilocybin that limits its use in research, Kirk talks openly about his experience with depression and the profound beneficial long-lasting effects of psilocybin therapy following the trial.

As one of the few people who have received this treatment; I fully appreciate the potential of psilocybin therapy for use with treatment-resistant depression. Shortly after the trial I remember thinking it was shocking that this treatment might never be widely available. I first met COMPASS to record a short film to talk about my experience. I was struck by their professionalism, ethics and commitment to patients.

Investors

Founding Seed Investors

ATAI Life Sciences is an internationally active biotech company investing in and acquiring therapeutics focusing on longevity and mental wellbeing. Galaxy Investment Partners, one of our Seed investors, has joined forces with ATAI on their COMPASS investment.

Thiel Capital provides strategic and operational support for Peter Thiel’s many investment initiatives and entrepreneurial endeavours.

Series A Investors

ATAI Life Sciences is an internationally active biotech company investing in and acquiring therapeutics focusing on longevity and mental wellbeing.

Principia SGR is one of the leading Italian Venture and Growth Capital funds focused on healthcare and life sciences.

Subversive Capital is dedicated to investing in radical companies whose core missions subvert the status quo and require sophisticated government and regulatory strategies for success.

Thiel Capital provides strategic and operational support for Peter Thiel’s many investment initiatives and entrepreneurial endeavours.

Others

Other investors include prominent investment entities (eg funds, family offices) and individuals.